Literature DB >> 11855844

Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

Volker Viereck1, Günter Emons, Vanessa Lauck, Karl-Heinz Frosch, Sabine Blaschke, Carsten Gründker, Lorenz C Hofbauer.   

Abstract

Bisphosphonates are potent antiresorptive drugs commonly employed in the treatment of metabolic bone diseases. Despite their frequent use, the mechanisms of bisphosphonates on bone cells have largely remained unclear. Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast formation and activation, whereas osteoprotegerin (OPG) neutralizes RANKL. Various osteotropic drugs have been demonstrated to modulate osteoblastic production of RANKL and OPG. In this study, we assessed the effects of the bisphosphonates pamidronate (PAM) and zoledronic acid (ZOL) on OPG mRNA steady-state levels (by semiquantitative RT-PCR) and protein production (by ELISA) in primary human osteoblasts (hOB). PAM increased OPG mRNA levels and protein secretion by hOB by up to 2- to 3-fold in a dose-dependent fashion with a maximum effect at 10(-6) M (P < 0.001) after 72 h. Similarly, ZOL enhanced OPG gene expression and protein secretion by hOB in a dose-dependent fashion with a maximum effect at 10(-8) M after 72 h, consistent with the higher biological potency of ZOL. Time course experiments indicated a stimulatory effect of PAM and ZOL on osteoblastic OPG protein secretion by 6-fold, respectively (P < 0.001). Pretreatment with PAM and ZOL prevented the inhibitory effects of the glucocorticoid dexamethasone on OPG mRNA and protein production. Analysis of cellular markers of osteoblastic differentiation revealed that PAM and ZOL induced type I collagen secretion and alkaline phosphatase activity by 2- and 4-fold, respectively (P < 0.0001 by ANOVA). In conclusion, our data suggest that bisphosphonates modulate OPG production by normal human osteoblasts, which may contribute to the inhibition of osteoclastic bone resorption. Since, OPG production increases with osteoblastic cell maturation, enhancement of OPG by bisphosphonates could be related to their stimulatory effects on osteoblastic differentiation. ©2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11855844     DOI: 10.1006/bbrc.2002.6510

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  71 in total

Review 1.  Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.

Authors:  Teresita Bellido; Lilian I Plotkin
Journal:  Bone       Date:  2010-08-18       Impact factor: 4.398

2.  Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures.

Authors:  Yuwei Wang; Alexandra Panasiuk; David W Grainger
Journal:  Mol Pharm       Date:  2011-01-21       Impact factor: 4.939

Review 3.  Bone disease in multiple myeloma.

Authors:  Øyvind Hjertner; Therese Standal; Magne Børset; Anders Sundan; Anders Waage
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 4.  Bisphosphonates: effects on osteoblast.

Authors:  Nicola Maruotti; Addolorata Corrado; Anna Neve; Francesco Paolo Cantatore
Journal:  Eur J Clin Pharmacol       Date:  2012-02-09       Impact factor: 2.953

5.  Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films.

Authors:  Rebecca S Hayden; Moritz Vollrath; David L Kaplan
Journal:  Acta Biomater       Date:  2013-10-01       Impact factor: 8.947

Review 6.  [Bisphosphonates for malignant bone tumors].

Authors:  G Holzer
Journal:  Orthopade       Date:  2009-04       Impact factor: 1.087

Review 7.  Hormesis and medicine.

Authors:  Edward J Calabrese
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

8.  Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy-histomorphometric and immunohistochemical analysis.

Authors:  Miguel Luciano Silva; Leandro Tasso; Alan Arrieira Azambuja; Maria Antonia Figueiredo; Fernanda Gonçalves Salum; Vinicius Duval da Silva; Karen Cherubini
Journal:  Clin Oral Investig       Date:  2016-03-09       Impact factor: 3.573

9.  Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition.

Authors:  Michaël Chaplet; Cédric Detry; Christophe Deroanne; Larry W Fisher; Vincent Castronovo; Akeila Bellahcéne
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

10.  Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells.

Authors:  Jun Chang; Wei Wang; Hui Zhang; Yong Hu; Zongsheng Yin
Journal:  Oncol Lett       Date:  2012-05-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.